Cargando…

Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial

IRL790 is a novel compound with psychomotor stabilizing properties primarily targeting the dopamine D3 receptor. IRL790 is developed as an experimental treatment for levodopa-induced dyskinesia (LID), impulse control disorder, and psychosis in Parkinson’s disease (PD). The primary objective was to i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Svenningsson, Per, Johansson, Anders, Nyholm, Dag, Tsitsi, Panagiota, Hansson, Fredrik, Sonesson, Clas, Tedroff, Joakim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283839/ https://www.ncbi.nlm.nih.gov/pubmed/30534585 http://dx.doi.org/10.1038/s41531-018-0071-3

Ejemplares similares

A first‐in‐human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers
por: Sjöberg, Folke, et al.
Publicado: (2021)

Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease
por: Bergquist, Filip, et al.
Publicado: (2022)

“Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Schaeffer, Eva, et al.
Publicado: (2016)

Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
por: Grétarsdóttir, Helga María, et al.
Publicado: (2021)

Effects of Helicobacter pylori on Levodopa Pharmacokinetics
por: Nyholm, Dag, et al.
Publicado: (2021)

Involvement of Autophagy in Levodopa‐Induced Dyskinesia
por: Feyder, Michael, et al.
Publicado: (2021)

Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
por: Bargiotas, Panagiotis, et al.
Publicado: (2013)

Future Scenarios for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Cerasa, Antonio, et al.
Publicado: (2015)

Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
por: Krishnan, Syam, et al.
Publicado: (2017)

Cerebellar connectivity in Parkinson's disease with levodopa‐induced dyskinesia
por: Yoo, Han Soo, et al.
Publicado: (2019)

Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways
por: Green, Holly, et al.
Publicado: (2019)

The acute brain response to levodopa heralds dyskinesias in Parkinson disease
por: Herz, Damian M., et al.
Publicado: (2014)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Development of new levodopa treatment strategies in Parkinson’s disease—from bedside to bench to bedside
por: Aquilonius, Sten-Magnus, et al.
Publicado: (2017)

Vertical saccades and antisaccades: complementary markers for motor and cognitive impairment in Parkinson’s disease
por: Waldthaler, Josefine, et al.
Publicado: (2019)

Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson’s disease patients
por: Senek, Marina, et al.
Publicado: (2018)

Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease
por: Teng, Long, et al.
Publicado: (2014)

Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson's Disease
por: Guridi, J., et al.
Publicado: (2012)

Resting‐state connectivity predicts levodopa‐induced dyskinesias in Parkinson's disease
por: Herz, Damian M., et al.
Publicado: (2016)

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Pagano, Gennaro, et al.
Publicado: (2017)

Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation
por: Li, Michael H., et al.
Publicado: (2018)

Altered interhemispheric synchrony in Parkinson’s disease patients with levodopa-induced dyskinesias
por: Gan, Caiting, et al.
Publicado: (2020)

White matter hyperintensities and risk of levodopa‐induced dyskinesia in Parkinson’s disease
por: Chung, Seok Jong, et al.
Publicado: (2020)

Nigral Iron Deposition Is Associated With Levodopa-Induced Dyskinesia in Parkinson’s Disease
por: Song, Tianbin, et al.
Publicado: (2021)

Exome-wide association study of levodopa-induced dyskinesia in Parkinson’s disease
por: König, Eva, et al.
Publicado: (2021)

Pallidal Structural Changes Related to Levodopa-induced Dyskinesia in Parkinson's Disease
por: Youn, Jinyoung, et al.
Publicado: (2022)

Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies
por: Kwon, Destany K., et al.
Publicado: (2022)

Investigation of PRKN Mutations in Levodopa-Induced Dyskinesia in Parkinson’s Disease Treatment
por: Bispo, Ana Gabrielle, et al.
Publicado: (2023)

Dopamine pathway and Parkinson's risk variants are associated with levodopa-induced dyskinesia
por: Sosero, Yuri L., et al.
Publicado: (2023)

Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington’s Disease
por: Waters, Susanna, et al.
Publicado: (2018)

Levodopa/carbidopa microtablets in Parkinson’s disease: a study of pharmacokinetics and blinded motor assessment
por: Senek, Marina, et al.
Publicado: (2017)

Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance
por: Nyholm, Dag, et al.
Publicado: (2022)

LOW DOSE LEVODOPA IN TARDIVE DYSKINESIA
por: Sethi, Sujata, et al.
Publicado: (1990)

Synaptic proteins in CSF relate to Parkinson’s disease stage markers
por: Bereczki, Erika, et al.
Publicado: (2017)

Ranitidine reduced levodopa-induced dyskinesia in a rat model of Parkinson’s disease
por: Cui, Guiyun, et al.
Publicado: (2013)

Effect of Subthalamic Deep Brain Stimulation on Levodopa-Induced Dyskinesia in Parkinson's Disease
por: Kim, Ji Hee, et al.
Publicado: (2015)

Factors Predictive of the Development of Levodopa-Induced Dyskinesia and Wearing-Off in Parkinson's Disease
por: Rajput, Ali H
Publicado: (2014)

Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
por: Pahwa, Rajesh, et al.
Publicado: (2015)

Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
por: Antonini, Angelo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1a42bbnnl9gfo6rk4ejt5nb13r